China's thriving biotech sector is drawing foreign companies into joint research and development (R&D). For those seeking to collaborate, including on clinical trials, understanding the regulatory framework governing Human Genetic Resources (HGR) is essential. This article provides insights into the HGR regulations and implementation rules and outlines strategies to ensure compliance while mitigating enforcement risks.

Understanding Chinese HGR regulations

In recent years, China has built a comprehensive regulatory framework for managing HGR, primarily through the Human Genetic Resources Administration Regulation and its Implementation Rules. Under these regulations, any collection, storage, use, or transfer of HGR materials or related data from Chinese citizens for research or clinical trial purposes requires prior approval or record-filing with the National Health Commission.

Navigating this approval process can be challenging for foreign companies. To ensure compliance, it is critical to prepare a well-structured application dossier and agreements that clearly define parties involved, research objectives, intended use of HGR, intellectual property arrangements, and data management.

Managing data flows

Once approvals or record filings are obtained or completed, managing genetic data flows becomes pivotal. Companies should implement robust data governance frameworks that comply with both Chinese data protection regulations and the laws of foreign companies' home jurisdictions. This includes establishing secure data storage solutions, ensuring sufficient informed consent from study subjects, and implementing strict access controls. Furthermore, companies should routinely audit their data management practices to identify potential vulnerabilities and mitigate risks.

Mitigating enforcement risks

Enforcement of HGR regulations in China has become increasingly stringent, with significant penalties for non-compliance. China's HGR regulatory framework, while complex, is clear and provides definitive guidance for foreign companies conducting R&D activities in China. Through proactive planning, well prepared filing documents and compliant operations, foreign companies should be able to leverage China's rich genetic resources and clinical data advantages to drive pharmaceutical R&D innovation.